MedTrace Logo

Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

NCT02790723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-04-15

No results posted yet for this study

Summary

This study seeks to determine the safety of three different doses of sc-rAAV2.5IL-1Ra delivered by intra-articular injection into one knee joint of patients with moderate OA of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

sc-rAAV2.5IL-1Ra

Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Sponsors & Collaborators

Principal Investigators

  • Christopher H. Evans, Ph.D. · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-05
Primary Completion
2022-03-17
Completion
2022-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02790723 on ClinicalTrials.gov